eli lilly

Eli Lilly and Co. (NYSE:LLY) revealed plans to inject an extra $4.5 billion into two of its Indiana manufacturing sites on Wednesday. This move escalates its total capital expansion in the state since 2020 to over $21 billion. The additional funding is intended to support the production of...

In the face of a frothy market, financial expert Jim Cramer encourages investors to stay the course, highlighting numerous positive stock narratives that counterbalance the market’s irrationality. What Happened: Cramer made a case last week, asserting that the current market...

Novo Nordisk A/S (NYSE:NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables. What Happened: On Wednesday, during Novo’s first quarter earnings call...

On Tuesday, the Dow Jones Industrial Average rose by 0.4%, closing at $39,331.85, while the S&P 500 also ended the day in positive territory, increasing by 0.6% to finish at 5,509.01. Additionally, the Nasdaq gained 0.8%, closing at 18,028.76. These are the top stocks that gained the attention...

Ross Gerber, a prominent Tesla investor, has suggested that using Ozempic could lead to significant cost savings. What Happened: Gerber took to X (formerly Twitter) to share his thoughts on the potential financial benefits of using Ozempic, a weight-loss drug developed by Novo Nordisk A/S (NYSE:NVO...

During Tuesday’s CNBC Investing Club Morning Meeting, U.S. stocks exhibited mixed performance, prompting a closer look at prevailing market themes. Cybersecurity emerged as a key focus, with Jim Cramer emphasizing heightened threats following a recent breach at UnitedHealth. What Happened:...

Jim Cramer, the host of CNBC’s “Mad Money,” has issued a warning to investors about the potential impact of weight loss drugs, such as Ozempic and Wegovy, on the food and beverage industry. What Happened: Cramer cautioned investors on Monday about the growing popularity of GLP-1s...

Jim Cramer, the host of CNBC’s “Mad Money,” expressed skepticism regarding the recent market movements of Apple Inc (NASDAQ:AAPL), Chipotle Mexican Grill, Inc. (NYSE:CMG), and Eli Lilly And Co (NYSE:LLY). What Happened: On Wednesday, Cramer questioned the rationale behind the...

Tesla Inc. (NASDAQ:TSLA) has been surpassed in market value by pharmaceutical giant Eli Lilly (NYSE:LLY), following a 12% single-day plunge in Tesla’s stock. What Happened: Tesla’s fourth-quarter earnings report, which fell short of revenue and profit expectations, triggered a...

Jim Cramer, the host of CNBC’s “Mad Money,” has hinted at the possibility of Tesla Inc (NASDAQ:TSLA) being replaced by Eli Lilly and Co (NYSE:LLY) in the “Magnificent Seven” list of mega-cap stocks. What Happened: Cramer, in his show on Monday, suggested that Tesla...

U.S. stock markets gave a mixed picture on Thursday with the Dow Jones inching up 0.03% to 37,440.34. The S&P 500 and Nasdaq fell 0.34% and 0.56% to 4,688.68 and 14,510.30 respectively. These are the top stocks that gained the attention of retail traders and investors throughout the day:...

Jim Cramer does not recommend investors to buy Eli Lilly (NASDAQ:LLY) stocks yet, despite the recent jump, CNBC reports. Responding to an email query, Cramer mentioned a new 12-month price target of $600 for Eli Lilly. Despite the promising outlook, the rapid ascent of Eli Lilly’s stock has...

Groundbreaking data from Eli Lilly & Co. (NYSE:LLY) has sparked a new conversation about obesity treatments, with their experimental drug, retatrutide, showing astonishing weight loss results, Bloomberg reports. Unprecedented Weight Loss Retatrutide has demonstrated remarkable efficacy in a mid...

A fake account with the handle @EliLillyandCo posted last week on Twitter that Eli Lilly And Co (NYSE: LLY) is giving away free insulin.  Responding to the fake report, the company clarified that the account from which the message was sent was not the Twitter handle for the actual...

The cover story in this weekend's Barron's examines how teenage traders are shaking up the market. Other featured articles discuss which drugmakers benefit from a new market, why it is time to buy momentum stocks and how to safely hunt for yield. Also, see the prospects for a semiconductor...